

**Council of Scientific & Industrial Research**  
(वैज्ञानिक तथा औद्योगिक अनुसंधान परिषद)  
**Research Project Planning and Business Development Directorate (RPPBDD)**  
अनुसंधान, परियोजना योजना तथा व्यवसाय विकास निदेशालय (आरपीपीबीडीडी)

Anusandhan Bhavan, 2, Rafi Marg, New Delhi 110001


**No. 13/47/2020-RPPBDD**

**April 14, 2020**

**OFFICE MEMORANDUM/ कार्यालयज्ञापन**

**Sub: Technology & Intellectual Property guidelines for Covid-19 related technologies/products developed by CSIR laboratories.**

1. Whole world is currently going through the crisis of Covid-19 pandemic. In order to tackle this situation, many of the CSIR laboratories are tirelessly working and developing different products, technologies, health devices, drugs, kits, materials, PPEs etc. to combat the Covid-19 epidemic, as a disaster management strategy.
2. In this time of grave crisis, it is very much desirable that the technology licensing & knowledge transfer for technologies/products developed by CSIR labs is facilitated, enabling mass production by Industry to support urgent requirements of the country.
3. Under such unprecedented situation, as a proactive measure, DG, CSIR and Secretary, DSIR in capacity of Chairman of the Governing Body of CSIR has approved that following guidelines would be applicable for technology/product licensing of Covid-19 related technologies/ products developed by CSIR:
  - a. Licensing of Knowledgebase / Intellectual Property shall be on non-exclusive basis;
  - b. The upfront payment of ToT (Transfer of Technology/licensing of knowledge ) / Royalty from ToT partner may be deferred for six months or up to the applicability of NDMA (National Disaster Management ACT) whichever is earlier on mutually agreed terms and conditions.;
  - c. Clause for deferred Royalty / Upfront payment and co-branding shall be included as an integral part of the agreement;
  - d. The low cost technologies classified as Personal Protective Equipment (PPE) such as hand sanitizers, disinfects sprays, disinfect chambers, mobile disinfect kits, surgical masks, bio medical gowns, hand gloves, face shields, Covid testing kits etc. may be transferred to MSME/ Startups as open source technologies. The permission of licensing of production of open source technologies shall be limited to the fix period of six months or till the applicability of NDMA whichever is earlier. The clause for co-branding may be included while permitting licensing;
  - e. Director of the laboratories can form a three-member committee to classify open source technologies and permit limited production licensing as per clause (d). For issues related to CSIR Hqs, DG, CSIR shall be the competent authority;
  - f. Agreement/ MoUs signed through email will be acceptable, considering the lockdown prevailing due to COVID-19 pandemic. Proper agreements signing on stamp/judicial papers can be done after lifting of lockdown, however effective date of signing will remain the same as is finalised through email communications; and
  - g. Rest of the guidelines shall be as per the CSIR Guidelines for technology transfer and utilization of Knowledgebase-2017.

  
(के. वेंकटासुब्रामनियन)  
प्रभारी, आरपीपीबीडीडी

**Copy to:**

To The Concerned